Administration of dehydroepiandrosterone ameliorates experimental autoimmune neuritis in Lewis rats

Journal of Neuroimmunology

Volumn 207, Issue 1-2, 2009, Pages 39-44

  Tan, Xiao Dong ^a   Dou, Ying Chun ^b   Shi, Chang Wen ^a   Duan, Rui Sheng ^a   Sun, Ruo Peng ^c  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Cytokine; Dehydroepiandrosterone; Experimental autoimmune neuritis; Lymphocyte proliferation

Indexed keywords

FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 10; MYELIN; PRASTERONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG DOSE COMPARISON; EXPERIMENTAL AUTOIMMUNE NEURITIS; EXPERIMENTAL MODEL; FEMALE; GUILLAIN BARRE SYNDROME; INFLAMMATORY INFILTRATE; LEWIS RAT; LYMPHOCYTE PROLIFERATION; NEURITIS; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SPLEEN CELL; SUPERNATANT;

ADJUVANTS, IMMUNOLOGIC; ANALYSIS OF VARIANCE; ANIMALS; CATTLE; CELL PROLIFERATION; DEHYDROEPIANDROSTERONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FREUND'S ADJUVANT; INTERFERON-ALPHA; INTERFERON-GAMMA; MYELIN SHEATH; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; RATS; RATS, INBRED LEW; T-LYMPHOCYTES;

EID: 60149090741     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.11.011     Document Type: Article

References (32)

1. Auci D., Nicoletti F., Mangano K., Pieters R., Nierkens S., Morgan L., Offner H., Frincke J., and Reading C. Anti-inflammatory and immune regulatory properties of 5-androsten-3b, 17b-diol (HE2100), and synthetic analogue HE3204: implications for treatment of autoimmune diseases. Ann. N.Y. Acad. Sci. 1051 (2005) 730-742
2. Dillon J.S. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr. Drug Targets Inflamm. Allergy 4 (2005) 377-385
3. Du C., Guan Q., Khalil M.W., and Sriram S. Stimulation of Th2 response by high doses of dehydroepiandrosterone in KLH-primed splenocytes. Exp. Biol. Med. (Maywood) 226 (2001) 1051-1060
4. Du C., Khalil M.W., and Sriram S. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J Immunol. 167 (2001) 7094-7101
5. Duan R.S., Link H., and Xiao B.G. Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats. J. Clin. Immunol. 23 (2003) 100-106
6. Elkarim R.A., Dahle C., Mustafa M., Press R., Zou L.P., Ekerfelt C., Ernerudh J., Link H., and Bakhiet M. Recovery from Guillain-Barré syndrome is associated with increased levels of neutralizing autoantibodies to interferon-gamma. Clin. Immunol. Immunopathol. 88 (1998) 241-248
7. Hohnoki K., Inoue A., and Koh C.S. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J. Neuroimmunol. 87 (1998) 27-32
8. Hughes R.A., and Cornblath D.R. Guillain-Barré syndrome. Lancet 366 (2005) 1653-1666
9. Kipper-Galperin M., Galilly R., Danenberg H.D., and Brenner T. Dehydroepiandrosterone selectively inhibits production of tumor necrosis factor-α and interlukin-6 in astrocytes. Int. J. Dev. Neurosci. 17 (1999) 765-775
10. Kuwabara S. Guillain-Barré syndrome. Curr. Neurol. Neurosci. Rep. 7 (2007) 57-62
11. Mäurer M., and Gold R. Animal models of immune-mediated neuropathies. Curr. Opin. Neurol. 15 (2002) 617-622
12. Misawa S., Kuwabara S., Mori M., Kawaguchi N., Yoshiyama Y., and Hattori T. Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology 56 (2001) 666-669
13. Norton W.T., and Poduslo S.E. Myelination in rat brain: method of myelin isolation. J. Neurochem. 21 (1973) 749-757
14. Oberbeck R., Dahlweid M., Koch R., van Griensven M., Emmendörfer A., Tscherne H., and Pape H.C. Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Crit. Care Med. 29 (2001) 380-384
15. Offner H., Zamora A., Drought H., Matejuk A., Auci D.L., Morgan E.E., Vandenbark A.A., and Reading C.L. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. J. Neuroimmunol. 30 (2002) 128-139
16. Offner H., Zamora A., Subramanian S., Polanczyk M., Krogstad A., Auci D.L., Morgan E.E., and Reading C.L. A synthetic androstene analogue inhibits collagen-induced arthritis in the mouse. Clin. Immunol. 110 (2004) 181-190
17. Powell J.M., and Sonnenfeld G. The effects of dehydroepiandrosterone (DHEA) on in vitro spleen cell proliferation and cytokine production. J. Interferon. Cytokine Res. 26 (2006) 34-39
18. Radhakrishnan V.V., Sumi M.G., Reuben S., Mathai A., and Nair M.D. Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome. Acta Neurol. Scand. 109 (2004) 71-74
19. Redford E.J., Hall S.M., and Smith K.J. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 118 (1995) 869-878
20. Röntzsch A., Thoss K., Petrow P.K., Henzgen S., and Bräuer R. Amelioration of murine antigen-induced arthritis by dehydroepiandrosterone (DHEA). Inflamm. Res. 53 (2004) 189-198
21. Sharief M.K., Ingram D.A., and Swash M. Circulating tumor necrosis factor-alpha correlates with electrodiagnostic abnormalities in Guillain-Barré syndrome. Ann. Neurol. 42 (1997) 68-73
22. Straub R.H., Schölmerich J., and Zietz B. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases-substitutes of adrenal and sex hormones. Z. Rheumatol. 59 Suppl 2:II (2000) 108-118
23. Svec F., and Porter J.R. The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc. Soc. Exp. Biol. Med. 218 (1998) 174-191
24. van Vollenhoven R.F. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin. Pharmacother. 3 (2002) 23-31
25. van Vollenhoven R.F., Morabito L.M., Engleman E.G., and McGuire J.L. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J. Rheumatol. 25 (1998) 285-289
26. von Mühlen D., Laughlin G.A., Kritz-Silverstein D., and Barrett-Connor E. The Dehydroepiandrosterone And WellNess (DAWN) study: research design and methods. Contemp. Clin. Trials 28 (2007) 153-168
27. Weishaupt A., Brück W., Hartung T., Toyka K.V., and Gold R. Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-alpha. Neurosci. Lett. 306 (2001) 77-80
28. Yang B.C., Liu C.W., Chen Y.C., and Yu C.K. Exogenous dehydroepiandrosterone modified the expression of T helper-related cytokines in NZB/NZW F1 mice. Immunol. Invest. 27 (1998) 291-302
29. Yoneda M., Wada K., Katayama K., Nakajima N., Iwasaki T., Osawa E., Mukasa K., Yamada Y., Blumberg R.S., Sekihara H., and Nakajima A. A novel therapy for acute hepatitis utilizing dehydroepiandrosterone in the murine model of hepatitis. Biochem. Pharmacol. 68 (2004) 2283-2289
30. Yu C.K., Yang B.C., Lei H.Y., Chen Y.C., Liu Y.H., Chen C.C., and Liu C.W. Attenuation of house dust mite Dermatophagoides farinae-induced airway allergic responses in mice by dehydroepiandrosterone is correlated with down-regulation of TH2 response. Clin. Exp. Allergy 29 (1999) 414-422
31. Zhu J., Mix E., and Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J. Neuroimmunol. 84 (1998) 40-52
32. Zhu Y., Ljunggren H.G., Mix E., Li H.L., van der Meide P., Elhassan A.M., Winblad B., and Zhu J. Suppression of autoimmune neuritis in IFN-gamma receptor-deficient mice. Exp. Neurol. 169 (2001) 472-478